Table 1.

Cardiac morphometry, haemodynamics, and echocardiographic findings at the end of study

Parameters	Sham	Infarction
		Vehicle	Nic	Glib	Nic + Glib	Fasudil	Fas + Glib
No. of rats	10	10	12	11	11	9	9
Body weight, g	365 ± 25	372 ± 21	382 ± 21	377 ± 22	373 ± 20	392 ± 25	390 ± 27
HR, bpm	412 ± 23	394 ± 21	402 ± 18	419 ± 20	404 ± 16	415 ± 20	401 ± 18
LVESP, mm Hg	110 ± 8	98 ± 11	102 ± 7	103 ± 6	104 ± 8	96 ± 7	101 ± 8
LVEDP, mm Hg	6 ± 2	17 ± 3a	15 ± 3a	18 ± 4a	18 ± 3a	15 ± 3a	16 ± 5a
LVW/BW, mg/g	2.01 ± 0.11	3.13 ± 0.21a	2.89 ± 0.24a	3.22 ± 0.28a	3.05 ± 0.28a	2.82 ± 0.33a	3.22 ± 0.30a
RVW/BW, mg/g	0.45 ± 0.08	0.75 ± 0.10a	0.58 ± 0.07a, b	0.82 ± 0.11a	0.76 ± 0.12a	0.54 ± 0.05c	0.85 ± 0.11a
LungW/BW, mg/g	4.21 ± 0.55	5.89 ± 0.53a	4.69 ± 0.49b	5.98 ± 0.33a	5.59 ± 0.65a	4.29 ± 0.49c	5.65 ± 0.35a
+dp/dt, mm Hg/sec.	7816 ± 342	3093 ± 325a	4250 ± 253a , b	2834 ± 235a	2972 ± 264a	3882 ± 266a , c	3063 ± 227a
‐dp/dt, mm Hg/sec.	5986 ± 278	2874 ± 327a	3377 ± 222a , b	2762 ± 254a	2892 ± 253a	3291 ± 285a , d	3026 ± 262a
Infarct size, %	…	40 ± 2	38 ± 3	41 ± 3	40 ± 2	40 ± 2	41 ± 3
LVEDD, mm	5.8 ± 0.2	8.6 ± 0.5a	7.8 ± 0.5a , b	8.5 ± 0.4a	8.7 ± 0.5a	7.5 ± 0.4a , c	8.4 ± 0.5a
LVESD, mm	3.6 ± 0.2	7.2 ± 0.3a	5.7 ± 0.4a , b	7.1 ± 0.4a	7.2 ± 0.5a	5.4 ± 0.5a , c	7.1 ± 0.3a
FS (%)	38 ± 2	16 ± 4a	27 ± 4a , b	16 ± 3a	17 ± 4a	28 ± 4a , c	15 ± 4a

Values are mean ± SD. BW: body weight; Fas: fasudil; FS: fractional shortening; Glib: glibenclamide; HR: heart rate; LungW: lung weight; LVEDD: left ventricular end‐diastolic dimension; LVEDP: left ventricular end‐diastolic pressure; LVESD: left ventricular end‐systolic dimension; LVESP: left ventricular end‐systolic pressure; LVW: left ventricular weight; Nic: nicorandil; RVW: right ventricular weight.

^a P < 0.05 compared with sham.

^b P < 0.05 compared with infarcted groups treated with vehicle and nicorandil + glibenclamide.

^c P < 0.05 compared with infarcted groups treated with vehicle and fasudil + glibenclamide.

^d P < 0.05 compared with vehicle‐treated infarcted group.